2023
DOI: 10.1080/07357907.2023.2173773
|View full text |Cite
|
Sign up to set email alerts
|

Clinical validation of a ctDNA-Based Assay for Multi-Cancer Detection: An Interim Report from a Vietnamese Longitudinal Prospective Cohort Study of 2795 Participants

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
20
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
4

Relationship

2
6

Authors

Journals

citations
Cited by 20 publications
(24 citation statements)
references
References 42 publications
1
20
0
Order By: Relevance
“…Most (66.58%) participants were aged between 25-44 years, while the least proportion (1.61%) were aged above 65 years. In general, these data are similar to other KAP studies carried out elsewhere, most respondents claimed to belong to age groups of young people and young adults [15][16][17][18][19][20][21] . The majority (62.33%) of the participants were not married.…”
Section: Demographic Characteristics Of Study Participantssupporting
confidence: 88%
“…Most (66.58%) participants were aged between 25-44 years, while the least proportion (1.61%) were aged above 65 years. In general, these data are similar to other KAP studies carried out elsewhere, most respondents claimed to belong to age groups of young people and young adults [15][16][17][18][19][20][21] . The majority (62.33%) of the participants were not married.…”
Section: Demographic Characteristics Of Study Participantssupporting
confidence: 88%
“…It has been well established that blood hemolysis causes genomic DNA (gDNA) and hemoglobin contamination which could interfere with the performance of liquid biopsy tests 26 . To assess the impact of these two potential interferents, we generated 30 pooled plasma samples, including cancer (N=20) and healthy control (N=10).…”
Section: Resultsmentioning
confidence: 99%
“…Lastly, this was a retrospective cohort study and may be biased by the nature of this study design. In an interim 6-month report of a prospective study named K-DETEK, we were encouraged by the preliminary data demonstrated the ability of SPOT-MAS to detect cancer patients who exhibited no symptoms at the time of testing (59). Despite these promising results, the performance of SPOT-MAS as an early cancer screening test remains to be fully validated in a large, multi-center prospective study with 1 to 2 years of follow up.…”
Section: Discussionmentioning
confidence: 99%